Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Thiosulfate Eye Drops for SYD985-Induced Ocular Toxicity
NCT04983238Phase 2Completed
- Sponsor
- Byondis
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Ocular toxicity comparing BYON5667 & SYD985 with Placebo & SYD985 (2 arms). Primary endpoint: Percentage of patients with SYD985-related ocular adverse events Grade >=1 at Day 63. Started Jan 2022; status: completed.
02
Drugs
sodium thiosulfate
03
Conditions
Ocular toxicity
Beyond the preview
Go deeper on NCT04983238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983238.